Drug Development for Alzheimer's Disease: Recent Progress
Experimental Neurobiology
;
: 120-131, 2010.
Article
Dans Anglais
| WPRIM
| ID: wpr-122585
ABSTRACT
Alzheimer's disease, the most common cause of dementia, is characterized by two major pathological hallmarks amyloid plaques and neurofibrillary tangles. Based on these two indicators, an amyloid cascade hypothesis was proposed, and accordingly, most current therapeutic approaches are now focused on the removal of beta-amyloid peptides (Abeta from the brain. Additionally, strategies for blocking tau hyperphosphorylation and aggregation have been suggested, including the development of drugs that can block the formation of tangles. However, there are no true disease-modifying drugs in the current market, though many drugs based on theories other than Abeta and tau pathology are under development. The purpose of this review was to provide information on the current development of AD drugs and to discuss the issues related to drug development.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Peptides
/
Encéphale
/
Enchevêtrements neurofibrillaires
/
Plaque amyloïde
/
Démence
/
Maladie d'Alzheimer
/
Amyloïde
langue:
Anglais
Texte intégral:
Experimental Neurobiology
Année:
2010
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS